Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study
The aim of the present study is to compare the short-term effects of gliclazide and glibenclamide on the oxidative state and vascular endothelium function of Type 2 diabetic patients in an observer-blinded, randomized crossover study. Thirteen Type 2 diabetic patients were enrolled: one group of sev...
Gespeichert in:
| Veröffentlicht in: | Journal of diabetes and its complications 2006-05, Vol.20 (3), p.179-183 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 183 |
|---|---|
| container_issue | 3 |
| container_start_page | 179 |
| container_title | Journal of diabetes and its complications |
| container_volume | 20 |
| creator | Shimabukuro, Michio Higa, Namio Takasu, Nobuyuki |
| description | The aim of the present study is to compare the short-term effects of gliclazide and glibenclamide on the oxidative state and vascular endothelium function of Type 2 diabetic patients in an observer-blinded, randomized crossover study. Thirteen Type 2 diabetic patients were enrolled: one group of seven patients took daily 160 mg of gliclazide for the first 4 weeks and then daily 5 mg of glibenclamide for the next 4 weeks; another group of six patients took daily 5 mg of glibenclamide for the first 4 weeks and 160 mg of gliclazide for the next 4 weeks. Forearm blood flow (FBF) measurement for endothelial function and biochemical analyses were conducted before and after each crossover treatment. Four weeks of treatment with either sulfonylurea showed the similar antihyperglycemic effects and enhancement of the peak FBF and total reactive hyperemic flow (flow debt repayment: FDR) during reactive hyperemia. Treatment with gliclazide resulted in the significant reduction to about 60% of baseline in urinary 8-iso-prostaglandin F2alpha (8iPGF2alpha) excretion while no such change was detected in the glibenclamide period. The increases in peak FBF and FDR were in parallel with its anti-hyperglycemic effect, but not with antioxidant state. Results suggest that gliclazide and glibenclamide can protect vascular endothelium from hyperglycemia-induced injury in Type 2 diabetic patients. |
| doi_str_mv | 10.1016/j.jdiacomp.2005.06.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67887959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67887959</sourcerecordid><originalsourceid>FETCH-LOGICAL-p237t-94bf32eb620209b281e314d8515bef340ff4039603c5adba493aa7057a2c804d3</originalsourceid><addsrcrecordid>eNpdkM1q3TAQhUVJaH7aVwiCQHZ2R5Il29mVS5MGAt0kkJ2RpXGri225khxy7zP0oaPbppuszpnhm8NhCLlgUDJg6su23FqnjZ-WkgPIElQJjH8gp6ypRVEpeDrKHqQqmprXJ-Qsxi0AKCnZR3LClBKci-aU_NnkCB1c9DP1A02_kOo5Of_ibNbsLX3W0ayjDhSHAU2KB-7n6Myo987iXySPPc55Mx02bqYPuwUpp7lij8kZuujkcE7xmmoa8oWf3B4tNcHH6J8x0JhWu_tEjgc9Rvz8pufk8ebbw-Z7cf_j9m7z9b5YuKhT0Vb9IDj2igOHtucNQ8Eq20gmexxEBcNQgWgVCCO17XXVCq1rkLXmpoHKinNy9S93Cf73ijF1k4sGx1HP6NfYqbpp6la2Gbx8B279GubcrWMghJCt5DJTF2_U2k9ouyW4SYdd9__L4hXMAoMO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1033359525</pqid></control><display><type>article</type><title>Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Shimabukuro, Michio ; Higa, Namio ; Takasu, Nobuyuki</creator><creatorcontrib>Shimabukuro, Michio ; Higa, Namio ; Takasu, Nobuyuki</creatorcontrib><description>The aim of the present study is to compare the short-term effects of gliclazide and glibenclamide on the oxidative state and vascular endothelium function of Type 2 diabetic patients in an observer-blinded, randomized crossover study. Thirteen Type 2 diabetic patients were enrolled: one group of seven patients took daily 160 mg of gliclazide for the first 4 weeks and then daily 5 mg of glibenclamide for the next 4 weeks; another group of six patients took daily 5 mg of glibenclamide for the first 4 weeks and 160 mg of gliclazide for the next 4 weeks. Forearm blood flow (FBF) measurement for endothelial function and biochemical analyses were conducted before and after each crossover treatment. Four weeks of treatment with either sulfonylurea showed the similar antihyperglycemic effects and enhancement of the peak FBF and total reactive hyperemic flow (flow debt repayment: FDR) during reactive hyperemia. Treatment with gliclazide resulted in the significant reduction to about 60% of baseline in urinary 8-iso-prostaglandin F2alpha (8iPGF2alpha) excretion while no such change was detected in the glibenclamide period. The increases in peak FBF and FDR were in parallel with its anti-hyperglycemic effect, but not with antioxidant state. Results suggest that gliclazide and glibenclamide can protect vascular endothelium from hyperglycemia-induced injury in Type 2 diabetic patients.</description><identifier>ISSN: 1056-8727</identifier><identifier>EISSN: 1873-460X</identifier><identifier>DOI: 10.1016/j.jdiacomp.2005.06.012</identifier><identifier>PMID: 16632238</identifier><language>eng</language><publisher>United States: Elsevier Limited</publisher><subject>Aged ; Antioxidants ; Antioxidants - therapeutic use ; Blood Flow Velocity - drug effects ; Blood Pressure - drug effects ; Body Mass Index ; Cross-Over Studies ; Diabetes Mellitus, Type 2 - drug therapy ; Dinoprost - analogs & derivatives ; Dinoprost - urine ; Double-Blind Method ; Female ; Forearm - blood supply ; Free radicals ; Gliclazide - therapeutic use ; Glucose ; Glyburide - therapeutic use ; Glycated Hemoglobin A - analysis ; Humans ; Hyperemia - diagnosis ; Male ; Middle Aged ; Oxidative stress ; Regional Blood Flow - drug effects ; Rodents ; Vascular Resistance - drug effects</subject><ispartof>Journal of diabetes and its complications, 2006-05, Vol.20 (3), p.179-183</ispartof><rights>2006 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1033359525?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16632238$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shimabukuro, Michio</creatorcontrib><creatorcontrib>Higa, Namio</creatorcontrib><creatorcontrib>Takasu, Nobuyuki</creatorcontrib><title>Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study</title><title>Journal of diabetes and its complications</title><addtitle>J Diabetes Complications</addtitle><description>The aim of the present study is to compare the short-term effects of gliclazide and glibenclamide on the oxidative state and vascular endothelium function of Type 2 diabetic patients in an observer-blinded, randomized crossover study. Thirteen Type 2 diabetic patients were enrolled: one group of seven patients took daily 160 mg of gliclazide for the first 4 weeks and then daily 5 mg of glibenclamide for the next 4 weeks; another group of six patients took daily 5 mg of glibenclamide for the first 4 weeks and 160 mg of gliclazide for the next 4 weeks. Forearm blood flow (FBF) measurement for endothelial function and biochemical analyses were conducted before and after each crossover treatment. Four weeks of treatment with either sulfonylurea showed the similar antihyperglycemic effects and enhancement of the peak FBF and total reactive hyperemic flow (flow debt repayment: FDR) during reactive hyperemia. Treatment with gliclazide resulted in the significant reduction to about 60% of baseline in urinary 8-iso-prostaglandin F2alpha (8iPGF2alpha) excretion while no such change was detected in the glibenclamide period. The increases in peak FBF and FDR were in parallel with its anti-hyperglycemic effect, but not with antioxidant state. Results suggest that gliclazide and glibenclamide can protect vascular endothelium from hyperglycemia-induced injury in Type 2 diabetic patients.</description><subject>Aged</subject><subject>Antioxidants</subject><subject>Antioxidants - therapeutic use</subject><subject>Blood Flow Velocity - drug effects</subject><subject>Blood Pressure - drug effects</subject><subject>Body Mass Index</subject><subject>Cross-Over Studies</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Dinoprost - analogs & derivatives</subject><subject>Dinoprost - urine</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Forearm - blood supply</subject><subject>Free radicals</subject><subject>Gliclazide - therapeutic use</subject><subject>Glucose</subject><subject>Glyburide - therapeutic use</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Humans</subject><subject>Hyperemia - diagnosis</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oxidative stress</subject><subject>Regional Blood Flow - drug effects</subject><subject>Rodents</subject><subject>Vascular Resistance - drug effects</subject><issn>1056-8727</issn><issn>1873-460X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkM1q3TAQhUVJaH7aVwiCQHZ2R5Il29mVS5MGAt0kkJ2RpXGri225khxy7zP0oaPbppuszpnhm8NhCLlgUDJg6su23FqnjZ-WkgPIElQJjH8gp6ypRVEpeDrKHqQqmprXJ-Qsxi0AKCnZR3LClBKci-aU_NnkCB1c9DP1A02_kOo5Of_ibNbsLX3W0ayjDhSHAU2KB-7n6Myo987iXySPPc55Mx02bqYPuwUpp7lij8kZuujkcE7xmmoa8oWf3B4tNcHH6J8x0JhWu_tEjgc9Rvz8pufk8ebbw-Z7cf_j9m7z9b5YuKhT0Vb9IDj2igOHtucNQ8Eq20gmexxEBcNQgWgVCCO17XXVCq1rkLXmpoHKinNy9S93Cf73ijF1k4sGx1HP6NfYqbpp6la2Gbx8B279GubcrWMghJCt5DJTF2_U2k9ouyW4SYdd9__L4hXMAoMO</recordid><startdate>200605</startdate><enddate>200605</enddate><creator>Shimabukuro, Michio</creator><creator>Higa, Namio</creator><creator>Takasu, Nobuyuki</creator><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>200605</creationdate><title>Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study</title><author>Shimabukuro, Michio ; Higa, Namio ; Takasu, Nobuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p237t-94bf32eb620209b281e314d8515bef340ff4039603c5adba493aa7057a2c804d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aged</topic><topic>Antioxidants</topic><topic>Antioxidants - therapeutic use</topic><topic>Blood Flow Velocity - drug effects</topic><topic>Blood Pressure - drug effects</topic><topic>Body Mass Index</topic><topic>Cross-Over Studies</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Dinoprost - analogs & derivatives</topic><topic>Dinoprost - urine</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Forearm - blood supply</topic><topic>Free radicals</topic><topic>Gliclazide - therapeutic use</topic><topic>Glucose</topic><topic>Glyburide - therapeutic use</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Humans</topic><topic>Hyperemia - diagnosis</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oxidative stress</topic><topic>Regional Blood Flow - drug effects</topic><topic>Rodents</topic><topic>Vascular Resistance - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shimabukuro, Michio</creatorcontrib><creatorcontrib>Higa, Namio</creatorcontrib><creatorcontrib>Takasu, Nobuyuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of diabetes and its complications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shimabukuro, Michio</au><au>Higa, Namio</au><au>Takasu, Nobuyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study</atitle><jtitle>Journal of diabetes and its complications</jtitle><addtitle>J Diabetes Complications</addtitle><date>2006-05</date><risdate>2006</risdate><volume>20</volume><issue>3</issue><spage>179</spage><epage>183</epage><pages>179-183</pages><issn>1056-8727</issn><eissn>1873-460X</eissn><abstract>The aim of the present study is to compare the short-term effects of gliclazide and glibenclamide on the oxidative state and vascular endothelium function of Type 2 diabetic patients in an observer-blinded, randomized crossover study. Thirteen Type 2 diabetic patients were enrolled: one group of seven patients took daily 160 mg of gliclazide for the first 4 weeks and then daily 5 mg of glibenclamide for the next 4 weeks; another group of six patients took daily 5 mg of glibenclamide for the first 4 weeks and 160 mg of gliclazide for the next 4 weeks. Forearm blood flow (FBF) measurement for endothelial function and biochemical analyses were conducted before and after each crossover treatment. Four weeks of treatment with either sulfonylurea showed the similar antihyperglycemic effects and enhancement of the peak FBF and total reactive hyperemic flow (flow debt repayment: FDR) during reactive hyperemia. Treatment with gliclazide resulted in the significant reduction to about 60% of baseline in urinary 8-iso-prostaglandin F2alpha (8iPGF2alpha) excretion while no such change was detected in the glibenclamide period. The increases in peak FBF and FDR were in parallel with its anti-hyperglycemic effect, but not with antioxidant state. Results suggest that gliclazide and glibenclamide can protect vascular endothelium from hyperglycemia-induced injury in Type 2 diabetic patients.</abstract><cop>United States</cop><pub>Elsevier Limited</pub><pmid>16632238</pmid><doi>10.1016/j.jdiacomp.2005.06.012</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1056-8727 |
| ispartof | Journal of diabetes and its complications, 2006-05, Vol.20 (3), p.179-183 |
| issn | 1056-8727 1873-460X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67887959 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Aged Antioxidants Antioxidants - therapeutic use Blood Flow Velocity - drug effects Blood Pressure - drug effects Body Mass Index Cross-Over Studies Diabetes Mellitus, Type 2 - drug therapy Dinoprost - analogs & derivatives Dinoprost - urine Double-Blind Method Female Forearm - blood supply Free radicals Gliclazide - therapeutic use Glucose Glyburide - therapeutic use Glycated Hemoglobin A - analysis Humans Hyperemia - diagnosis Male Middle Aged Oxidative stress Regional Blood Flow - drug effects Rodents Vascular Resistance - drug effects |
| title | Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T08%3A47%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20antioxidant%20and%20vascular%20effects%20of%20gliclazide%20and%20glibenclamide%20in%20Type%202%20diabetic%20patients:%20a%20randomized%20crossover%20study&rft.jtitle=Journal%20of%20diabetes%20and%20its%20complications&rft.au=Shimabukuro,%20Michio&rft.date=2006-05&rft.volume=20&rft.issue=3&rft.spage=179&rft.epage=183&rft.pages=179-183&rft.issn=1056-8727&rft.eissn=1873-460X&rft_id=info:doi/10.1016/j.jdiacomp.2005.06.012&rft_dat=%3Cproquest_pubme%3E67887959%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1033359525&rft_id=info:pmid/16632238&rfr_iscdi=true |